

Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

ONCOLOGY PHARMA, INC.

One Sansome Street
Suite 3500
San Francisco, CA 94104

(415) 869-1038
www.oncology-pharma.com
info@oncology-pharma.com
2834

Quarterly Report **For the Period Ending: September 30, 2022** (the "Reporting Period")

As of September 30, 2022, the number of shares outstanding of our Common Stock was:

37,963,216

As of June 30, 2022, the number of shares outstanding of our Common Stock was:

33,763,216

As of March 31, 2022, the number of shares outstanding of our Common Stock was:

33,763,216

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: No:

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: No:

Indicate by check mark whether a Change in Control¹ of the company has occurred over this reporting period:

¹ "Change in Control" shall mean any events resulting in:

(i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;

(ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;

(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or

(iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the OTC Markets Group Inc.

Yes: No:

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

Oncology Pharma, Inc., Nevada Corporation, Active
SourcingLink.net, Inc., Nevada Corporation until 4/2019
QCS.net Corporation, Delaware Corporation until 7/1999
Parkway Capital Corporation, Colorado, until 6/1994.

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

Nevada, Active

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

The address(es) of the issuer's principal executive office:

One Sansome Street
Suite 3500
San Francisco, CA 94104

The address(es) of the issuer's principal place of business:

Check box if principal executive office and principal place of business are the same address:

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: No:

If this issuer or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below:

2) Security Information

Trading symbol: ONPH

surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

Exact title and class of securities outstanding:	<u>Common</u>	
CUSIP:	<u>68235J 201</u>	
Par or stated value:	<u>\$0.001</u>	
Total shares authorized:	<u>900,000,000</u>	as of date: <u>September 30, 2022</u>
Total shares outstanding:	<u>37,963,216</u>	as of date: <u>September 30, 2022</u>
Number of shares in the Public Float ² :	<u>16,815,704</u>	as of date: <u>September 30, 2022</u>
Total number of shareholders of record:	<u>207</u>	as of date: <u>September 30, 2022</u>

All additional class(es) of publicly traded securities (if any):

Trading symbol:	<u>None</u>	
Exact title and class of securities outstanding:	_____	
CUSIP:	_____	
Par or stated value:	_____	
Total shares authorized:	_____	as of date: _____
Total shares outstanding:	_____	as of date: _____

Transfer Agent

Name: Olde Monmouth Stock Transfer Co. Inc.
Phone: (732) 872-2727
Email: matt@oldemonmouth.com
Address: 200 Memorial Pkwy, Atlantic Highlands, NJ 07716

Is the Transfer Agent registered under the Exchange Act?³ Yes: No:

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period.**

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods: See following Table.

² "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

³ To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

Date of Transaction	Transaction Type	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) OR Nature of Services Provided (if applicable)	Restricted or Unrestricted as of this filing?	Exemption or Registration Type?
Number of Shares outstanding as of April 1, 2019						Common:	1,248,961		
						Preferred:	1,000		
7/16/2019	New	1,000	common	\$ 0.01	No	Dr. Stefan Gruenwald	consulting	Restricted	4(a)(2)
8/26/2019	New	25,000	common	\$ 0.05	No	Kalos Therapeutics (Control Person: George Colberg)	Letter of Intent	Restricted	4(a)(2)
9/17/2019	New	85,000	common	\$ 0.03	No	Dr. Stefan Gruenwald	consulting	Restricted	4(a)(2)
10/30/2019	New	15,000	common	\$ 0.03	No	George Malasek	consulting	Restricted	4(a)(2)
10/30/2019	New	1,000	common	\$ 0.03	No	Daniel Chasse	consulting	Restricted	4(a)(2)
10/30/2019	New	5,000	common	\$ 0.03	No	Dimitrios Theofilopoulos	consulting	Restricted	4(a)(2)
11/12/2019	New	125,000	common	\$ 0.03	No	Bright Star International, Inc. (Control Person Kevin Dills)	Conversion of Debt	Unrestricted	Rule 144
11/12/2019	New	3,000	common	\$ 0.03	No	Dimitrios Theofilopoulos	consulting	Restricted	4(a)(2)
12/30/2019	Canceled	10,000	common	NA	NA	Vijay Mahant	NA	Restricted	NA
2/26/2020	New	2,500	common	\$ 0.02	No	NanoSmart Pharmaceuticals, Inc (Control Person Henry Smith)	License Fee	Restricted	4(a)(2)
Number of Shares outstanding on April 1, 2020						Common:	1,501,461		
						Preferred:	1,000		
8/11/2020	New	50,000	common	\$ 0.01	No	Kalos Therapeutics, Inc. (Control Person: George Colberg)	Letter of Intent	Restricted	4(a)(2)
8/18/2020	New	5,000	common	\$ 0.02	No	Henry Smith	consulting	Restricted	4(a)(2)
8/18/2020	New	5,000	common	\$ 0.02	No	James R. Smith	consulting	Restricted	4(a)(2)
8/18/2020	New	5,000	common	\$ 0.02	No	Dr. Argyrios Theofilopoulos, MD	consulting	Restricted	4(a)(2)
10/9/2020	New	515,000	common	\$ 0.70	No	Dimitrios Theofilopoulos	legal fees	Restricted	4(a)(2)
10/9/2020	New	500,000	common	\$ 0.70	No	George Malasek	officer compensation	Restricted	4(a)(2)
10/9/2020	New	255	common	\$ 0.70	No	Cede & Co.	reverse split rounding	Restricted	4(a)(2)
10/9/2020	New	350,000	common	\$ 0.70	No	James R. Smith	consulting	Restricted	4(a)(2)
10/9/2020	New	350,000	common	\$ 0.70	No	Dr. Argyrios Theofilopoulos	consulting	Restricted	4(a)(2)
10/9/2020	New	350,000	common	\$ 0.70	No	Henry Smith	consulting	Restricted	4(a)(2)
10/9/2020	New	10,000,000	common	\$ 0.70	No	Charles Wagner	director fee	Restricted	4(a)(2)
10/9/2020	New	2,500,000	common	\$ 0.70	No	Carlos Barnett	director fee	Restricted	4(a)(2)
10/9/2020	New	2,500,000	common	\$ 0.70	No	Shawn Crouse	director fee	Restricted	4(a)(2)
10/9/2020	New	2,500,000	common	\$ 0.70	No	Stefan Gruenwald	director fee	Restricted	4(a)(2)
10/22/2020	New	2,000,000	common	\$ 0.42	Yes	Bright Star International, Inc. (Control Person Kevin Dills)	Conversion of Debt	Unrestricted	Rule 144
10/27/2020	New	1,000,000	common	\$ 0.42	Yes	Life Sciences Journeys, Inc. (Control Person Karen Alanis)	Conversion of Debt	Unrestricted	Rule 144
10/30/2020	New	1,000,000	common	\$ 0.50	No	James B. Smith	officer compensation	Restricted	4(a)(2)
2/24/2021	New	1,700,000	common	\$ 36.50	Yes	Life Sciences Journeys, Inc. (Control Person Karen Alanis)	Conversion of Debt	Unrestricted	Rule 144
2/25/2021	New	500,000	common	\$ 39.00	Yes	Bright Star International, Inc. (Control Person Kevin Dills)	Conversion of Debt	Unrestricted	Rule 144
3/22/2021	New	6,500	common	\$ 36.50	No	Sybleu, Inc. (Control Person David Koos)	License fee	Restricted	4(a)(2)
Number of Shares outstanding on April 1, 2021						Common:	27,338,216		
						Preferred:	1,000		
4/12/2021	New	50,000	common	\$ 28.00	No	Regen Biopharma, Inc. (Control person: David Koos)	License fee	Restricted	4(a)(2)
5/5/2021	New	800,000	common	\$ 37.48	Yes	Life Sciences Journeys, Inc. (Control person: Kevin Dills)	Conversion of Debt	Unrestricted	Rule 144
8/4/2021		1,600,000	common	\$ 21.70	Yes	Bright Star International, Inc. (Control person: Kevin Dills)	Conversion of Debt	Unrestricted	Rule 144
8/6/2021		(25,000)	common	\$ 2.17	No	Kalos Therapeutics, Inc. (Control person: George Colberg)	Legal Settlement	Cancelled	Rule 144
9/22/2021		1,800,000	common	\$12.38	Yes	Bright Star International, Inc. (Control person: Kevin Dills)	Conversion of Debt	Unrestricted	Rule 144
11/17/2021		2,200,000	common	\$ 8.05	Yes	Bright Star International, Inc. (Control person: Kevin Dills)	Conversion of Debt	Unrestricted	Rule 144
7/14/2022		2,000,000	common	\$ 1.40	Yes	Bright Star International, Inc. (Control person: Kevin Dills)	Conversion of Debt	Unrestricted	Rule 144
8/25/2022		2,200,000	common	\$ 1.10	Yes	Bright Star International, Inc. (Control person: Kevin Dills)	Conversion of Debt	Unrestricted	Rule 144
Number of Shares outstanding on September 30, 2022						Common:	37,963,216		
						Preferred:	1,000		

B. Debt Securities, Including Promissory and Convertible Notes

The chart below lists and describes all outstanding promissory notes, convertible notes, convertible debentures, and any other debt instruments that may be converted into a class of the issuer's securities.

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount At issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms	Holder	Control Person	Reason
4/4/14	4,320	8,500	-	4/4/2014	0.0001	Bright Star International	Kevin Dills	Working Capital
11/25/16	2,000	2,000	-	11/25/2017	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
1/20/17	-	2,700	-	On Demand	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
4/3/17	3,000	3,000	-	On Demand	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
4/12/17	1,100	1,100	-	4/12/2018	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
5/5/17	30,000	30,000	-	5/5/2018	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
5/9/17	12,000	12,000	-	5/9/2018	0.0001	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
9/14/17	4,000	4,000	-	9/14/2018	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
10/30/17	3,500	3,500	-	10/30/2018	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
1/5/18	6,000	6,000	-	1/5/2019	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
1/18/18	1,000	1,000	-	1/18/2019	0.0001	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
3/5/18	3,000	3,000	-	3/5/2019	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
3/23/18	2,500	2,500	-	3/23/2019	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
4/20/18	3,500	3,500	-	4/20/2019	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
5/18/18	5,500	5,500	-	5/18/2019	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
7/20/18	1,500	1,500	-	7/20/2019	0.0080	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
8/6/18	300	1,100	-	8/6/2019	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
8/31/18	1,400	1,400	-	8/31/2019	0.0090	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
11/15/18	3,250	3,250	-	11/15/2019	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
1/1/19	3,500	3,500	-	1/1/2020	0.0007	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
1/15/19	1,100	1,100	-	1/15/2020	0.0007	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
1/23/19	4,200	4,200	-	1/23/2020	0.0050	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
2/8/19	1,750	1,750	-	2/8/2020	0.0007	Chester W. Mason	Chester W. Mason	Working Capital
3/1/19	2,500	2,500	-	On Demand	0.0050	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
3/6/19	3,500	3,500	-	On Demand	0.0050	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
4/6/19	3,000	3,000	-	4/5/2020	0.0007	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
6/25/19	1,050	1,050	-	6/24/2020	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
10/31/19	4,300	4,300	-	4/30/2020	0.0007	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
11/1/19	1,300	1,300	-	On Demand	0.0050	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
12/31/19	2,100	2,100	-	6/30/2020	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
3/11/20	3,500	3,500	-	On Demand	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
3/27/20	1,600	1,600	-	On Demand	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
4/6/2020	600	600	89	On Demand	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
4/15/2020	3,750	3,750	554	On Demand	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
4/30/2020	2,000	2,000	290	On Demand	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
5/21/2020	2,000	2,000	283	On Demand	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
5/29/2020	1,250	1,250	175	On Demand	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
6/30/2020	2,350	2,500	318	On Demand	0.0010	Charles Wagner	Charles Wagner	Working Capital
7/20/2020	6,000	6,000	791	On Demand	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
7/28/2020	5,500	5,500	718	On Demand	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
7/28/2020	2,500	2,500	326	On Demand	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
8/6/2020	10,000	10,000	1,290	On Demand	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
9/8/20	6,000	6,000	742	On Demand	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
9/15/20	750	750	92	On Demand	0.0015	Charles Wagner	Charles Wagner	Working Capital
9/22/20	450	450	55	On Demand	0.0015	Charles Wagner	Charles Wagner	Working Capital
10/19/20	4,000	4,000	468	On Demand	0.5100	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
10/20/20	3,000	3,000	350	On Demand	0.4200	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
11/19/20	800	800	89	On Demand	0.3500	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
12/4/20	2,000	2,000	199	On Demand	0.4700	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
2/1/21	1,000	1,000	100	On Demand	None	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
2/12/21	15,500	15,500	1,516	On Demand	5.0000	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
2/18/21	5,000	5,000	484	On Demand	None	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
3/24/21	40,000	40,000	3,649	On Demand	5.0000	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
4/14/21	60,000	60,000	10,534	On Demand	5.0000	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
5/18/21	5,000	5,000	822	On Demand	5.0000	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
6/30/21	5,000	5,000	751	On Demand	5.0000	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
8/18/21	55,000	55,000	7,378	On Demand	4.0000	Bright Star International	Kevin Dills	Working Capital
9/1/21	255,000	255,000	31,858	On Demand	3.0000	Bright Star International	Kevin Dills	Working Capital
12/29/21	35,000	35,000	3,164	On Demand	1.0000	Bright Star International	Kevin Dills	Working Capital
2/14/22	5,000	5,000	375	On Demand	1.0000	Bright Star International	Kevin Dills	Working Capital
3/25/22	5,000	5,000	311	On Demand	1.0000	Bright Star International	Kevin Dills	Working Capital
4/4/22	20,000	20,000	1,177	4/4/2023	1.0000	Bright Star International	Kevin Dills	Working Capital
4/15/22	6,000	6,000	331	4/15/2023	1.0000	Bright Star International	Kevin Dills	Working Capital
6/16/22	1,500	1,500	52	6/16/2023	0.5000	Bright Star International	Kevin Dills	Working Capital
7/20/22	2,000	2,000	47	7/20/2023	0.5000	Bright Star International	Kevin Dills	Working Capital
8/3/22	3,000	3,000	57	8/3/2023	0.4000	Bright Star International	Kevin Dills	Working Capital
9/13/22	5,000	5,000	28	9/13/2023	0.3000	Bright Star International	Kevin Dills	Working Capital
9/26/22	75,000	75,000	99	9/26/2023	0.2000	Bright Star International	Kevin Dills	Working Capital

4) Financial Statements

A. The following financial statements were prepared in accordance with:

- U.S. GAAP
 IFRS

B. The financial statements for this reporting period were prepared by (name of individual)⁴:

Name: James B. Smith
Title: Chief Financial Officer
Relationship to Issuer: Officer of Issuer

Provide the financial statements described below for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- C. Balance sheet;
- D. Statement of income;
- E. Statement of cash flows;
- F. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- G. Financial notes; and
- H. Audit letter, if audited

You may either (i) attach/append the financial statements to this disclosure statement or (ii) file the financial statements through OTCIQ as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

If you choose to publish the financial statements in a separate report as described above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to OTCIQ in the field below. Financial Statements must be compiled in one document.

The unaudited financial statements listed above are being posted to OTCIQ contemporaneously under the named file "Financial Statements – Quarterly Report – for the period ended September 30, 2022" and are incorporated by reference herein to this Disclosure Statement.

Financial statement information is considered current until the due date for the subsequent report (as set forth in the qualifications section above). To remain qualified for Current Information, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of each fiscal quarter-end date.

5) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. In answering this item, please include the following:

⁴ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills.

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

The licensing, development, manufacturing, and commercialization of therapeutic drugs and medical devices. Research is currently conducted by licensors.

B. Please list any subsidiaries, parents, or affiliated companies.

None

C. Describe the issuers' principal products or services.

Research, development, and commercialization of therapeutic drugs and medical devices designed for treatment of many types of cancers.

6) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

1. Licensing agreements allowing for revenue generation by the Company from the sale of drugs or medical devices in exchange for Company funding of research and development efforts of various licensors. In addition to upfront and ongoing payments for research and clinical development activities, the Company is usually required to pay the Licensor of the intellectual property rights a royalty during the term of the agreement which normally extends for much of the period of exclusivity of patent rights for the intellectual property.
2. Leased office facilities at the Company address of record. The lease includes various services and well as occupancy rights.

7) Company Insiders (Officers, Directors, and Control Persons)

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Using the tabular format below, please provide information, as of the period end date of this report, regarding any person or entity owning 5% of more of any class of the issuer's securities, as well as any officer, and any director of the company, or any person that performs a similar function, regardless of the number of shares they own. **If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.**

Name of Officer/Director or Control Person	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
<u>Charles Wagner</u>	<u>Chairman/Director</u>	<u>San Francisco, CA</u>	<u>10,600,004</u> 4	<u>Common</u> Common	<u>27.921%</u> <u>.0001%</u>	<u>Restricted</u> Unrestricted
<u>George Malasek</u>	<u>Chief Executive Officer</u>	<u>Frisco, TX</u>	<u>515,001</u>	<u>Common</u>	<u>1.357%</u>	<u>Restricted</u>
<u>James B. Smith</u>	<u>Chief Financial Officer</u>	<u>Kerrville, TX</u>	<u>1,000,000</u>	<u>Common</u>	<u>2.634%</u>	<u>Restricted</u>
<u>Carlos Barnett</u>	<u>Director</u>	<u>Carlsbad, CA</u>	<u>2,602,500</u>	<u>Common</u>	<u>6.855%</u>	<u>Restricted</u>
<u>Shawn Crouse</u>	<u>Director</u>	<u>Corte Madera, CA</u>	<u>2,603,500</u>	<u>Common</u>	<u>6.858%</u>	<u>Restricted</u>
<u>Stefan Gruenwald</u>	<u>Director</u>	<u>Encinitas, CA</u>	<u>2,586,000</u>	<u>Common</u>	<u>6.812%</u>	<u>Restricted</u>

8) Legal/Disciplinary History

A. Please identify whether any of the persons or entities listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

None

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None

9) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

Securities Counsel

Name: Dimitrios Theofilopoulos
Firm: Theo Law Firm
Address 1: 4225 Executive Square, Ste. 600
Address 2: La Jolla, CA 92037
Phone: (213) 359-3179
Email: dimitri@thelawfirm.com

Auditor

Name: Russ Boyer
Firm: dbbmckennon
Address 1: 20321 SW Birch Street, Suite 200
Address 2: Newport Beach, CA 92660-1756
Phone: (949) 200-3280
Email: rb@dbbmckennon.com

Investor Relations

Name: None
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s) or consultant(s) or provided assistance or services to the issuer during the reporting period.

Name: None
Firm: _____
Nature of Services: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, George Malasek certify that:

1. I have reviewed this Quarterly Disclosure Statement of Oncology Pharma, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

10/27/2022 [Date]

/s/George Malasek [Chief Executive Officer]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

Principal Financial Officer:

I, James B. Smith certify that:

1. I have reviewed this Quarterly Disclosure Statement of Oncology Pharma, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

10/27/2022 [Date]

/s/James B. Smith [Chief Financial Officer]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")